Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines

被引:7
|
作者
Zheng, Song-Yue
Yu, Bin
Zhang, Ke [1 ]
Chen, Min [1 ]
Hua, Yan-Hong
Yuan, Shuofeng [1 ]
Watt, Rory M. [2 ]
Zheng, Bo-Jian [1 ,1 ]
Yuen, Kwok-Yung [1 ]
Huang, Jian-Dong
机构
[1] Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Prince Philip Dent Hosp, Fac Dent, Sai Ying, Hong Kong, Peoples R China
关键词
Salmonella Typhimurium; Live oral vaccine; Soluble and insoluble antigens; Construction strategies; Immunological comparison; FOREIGN ANTIGENS; IMMUNE-RESPONSE; PLASMIDS; VACCINATION; DELIVERY; SURFACE; IMMUNOGENICITY; VECTORS; GENE; IDENTIFICATION;
D O I
10.1186/1471-2172-13-54
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Despite the development of various systems to generate live recombinant Salmonella Typhimurium vaccine strains, little work has been performed to systematically evaluate and compare their relative immunogenicity. Such information would provide invaluable guidance for the future rational design of live recombinant Salmonella oral vaccines. Result: To compare vaccine strains encoded with different antigen delivery and expression strategies, a series of recombinant Salmonella Typhimurium strains were constructed that expressed either the enhanced green fluorescent protein (EGFP) or a fragment of the hemagglutinin (HA) protein from the H5N1 influenza virus, as model antigens. The antigens were expressed from the chromosome, from high or low-copy plasmids, or encoded on a eukaryotic expression plasmid. Antigens were targeted for expression in either the cytoplasm or the outer membrane. Combinations of strategies were employed to evaluate the efficacy of combined delivery/expression approaches. After investigating in vitro and in vivo antigen expression, growth and infection abilities; the immunogenicity of the constructed recombinant Salmonella strains was evaluated in mice. Using the soluble model antigen EGFP, our results indicated that vaccine strains with high and stable antigen expression exhibited high B cell responses, whilst eukaryotic expression or colonization with good construct stability was critical for T cell responses. For the insoluble model antigen HA, an outer membrane expression strategy induced better B cell and T cell responses than a cytoplasmic strategy. Most notably, the combination of two different expression strategies did not increase the immune response elicited. Conclusion: Through systematically evaluating and comparing the immunogenicity of the constructed recombinant Salmonella strains in mice, we identified their respective advantages and deleterious or synergistic effects. Different construction strategies were optimally-required for soluble versus insoluble forms of the protein antigens. If an antigen, such as EGFP, is soluble and expressed at high levels, a low-copy plasmid-cytoplasmic expression strategy is recommended; since it provokes the highest B cell responses and also induces good T cell responses. If a T cell response is preferred, a eukaryotic expression plasmid or a chromosome-based, cytoplasmic-expression strategy is more effective. For insoluble antigens such as HA, an outer membrane expression strategy is recommended.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines
    Song-yue Zheng
    Bin Yu
    Ke Zhang
    Min Chen
    Yan-Hong Hua
    Shuofeng Yuan
    Rory M Watt
    Bo-Jian Zheng
    Kwok-Yung Yuen
    Jian-Dong Huang
    BMC Immunology, 13
  • [2] Evaluation of Salmonella enterica serovar Typhimurium and Choleraesuis slyA mutant strains for use in live attenuated oral vaccines
    Haneda, Takeshi
    Okada, Nobuhiko
    Kikuchi, Yuji
    Takagi, Masami
    Kurotaki, Tetsuro
    Miki, Tsuyoshi
    Arai, Setsuo
    Danbara, Hirofumi
    COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2011, 34 (05) : 399 - 409
  • [3] LIVE ORAL RECOMBINANT SALMONELLA CARRIER VACCINES
    SADOFF, J
    AGGARWAL, A
    BARON, L
    HONG, H
    ELSINGHORST, E
    LANAR, D
    WARREN, R
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (05) : 942 - 942
  • [4] THE DEVELOPMENT OF ORAL VACCINES BASED ON LIVE ATTENUATED SALMONELLA STRAINS
    CHATFIELD, S
    ROBERTS, M
    LONDONO, P
    CROPLEY, I
    DOUCE, G
    DOUGAN, G
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1993, 7 (01): : 1 - 7
  • [5] A Live Oral Recombinant Salmonella enterica Serovar Typhimurium Vaccine Expressing Clostridium perfringens Antigens Confers Protection against Necrotic Enteritis in Broiler Chickens
    Kulkarni, R. R.
    Parreira, V. R.
    Jiang, Y. -F.
    Prescott, J. F.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (02) : 205 - 214
  • [6] Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains
    Tennant, Sharon M.
    Wang, Jin-Yuan
    Galen, James E.
    Simon, Raphael
    Pasetti, Marcela F.
    Gat, Orit
    Levine, Myron M.
    INFECTION AND IMMUNITY, 2011, 79 (10) : 4175 - 4185
  • [7] LIVE ATTENUATED SALMONELLA VACCINES AND THEIR POTENTIAL AS ORAL COMBINED VACCINES CARRYING HETEROLOGOUS ANTIGENS
    HORMAECHE, CE
    JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 142 (01) : 113 - 120
  • [8] LIVE ORAL SALMONELLA VACCINES - POTENTIAL USE OF ATTENUATED STRAINS AS CARRIERS OF HETEROLOGOUS ANTIGENS TO THE IMMUNE-SYSTEM
    DOUGAN, G
    HORMAECHE, CE
    MASKELL, DJ
    PARASITE IMMUNOLOGY, 1987, 9 (02) : 151 - 160
  • [9] Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens
    Karem, KL
    Bowen, J
    Kuklin, N
    Rouse, BT
    JOURNAL OF GENERAL VIROLOGY, 1997, 78 : 427 - 434
  • [10] Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry
    Buckley, Anthony M.
    Wang, Jinhong
    Hudson, Debra L.
    Grant, Andrew J.
    Jones, Michael A.
    Maskell, Duncan J.
    Stevens, Mark P.
    VACCINE, 2010, 28 (04) : 1094 - 1105